Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000511

Drug Information
SynonymsLS-2304; o-Propionotoluidide, 2-(propylamino)-; KBioSS_002129; Prestwick1_000199; Spectrum_001649; NSC 40027; MolPort-005-935-583; CID4906; BSPBio_000157; Prilocaine [USAN]; Prilocainum; C13H20N2O; Prilocaine (USP/INN); 2-(Propylamino)-o-propionotoluidide; D00553; Prestwick2_000199; DivK1c_000846; N-(2-methylphenyl)-N2-propylalaninamide; Citanest; IDI1_000846; Propitocaine (JAN); 2-Methyl-alpha-propylaminopropionanilide; KBio2_007265; KBio2_004697; N-[2-Methylphenyl]-2-[propylamino]propanamide; Spectrum2_001549; Prilocaina [INN-Spanish]; o-Methyl-2-propylaminopropionanilide; prilocaine; KBio3_001824; AC-2100; Propitocaine; AC1L1J7W; BSPBio_002604; EINECS 211-957-0; Ambap1786-81-8; Spectrum3_001052; S1619_Selleck; Propanamide, N-(2-methylphenyl)-2-(propylamino)-; BPBio1_000173; CHEMBL1194; N-(2-Methylphenyl)-2-(propylamino)propanamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)- (9CI); DB00750; C07531; NCGC00162312-01; Prilocaina; BRN 2108498; NCGC00015860-03; HSDB 3386; KBio1_000846; Spectrum4_001192; I01-1860; Prestwick0_000199; o-Propionotuluidide, 2-propylamino-; L 67; Lopac0_001005; CHEBI:8404; 721-50-6; o-Methyl-alpha-propylaminopropionanilide; Astra 1515; Astra 1512; alpha-n-Propylamino-2-methylpropionanilide; AB00053665; NSC40027; SPBio_001398; BRD-A53952395-003-05-3; Prestwick3_000199; prilocaine base; o-Propionotoluidide, 2-propylamino-; UNII-046O35D44R; Prilocainum [INN-Latin]; KBio2_002129; 2-Methyl-.alpha.-propylaminopropionanilide; N-(2-methylphenyl)-N(2)-propylalaninamide; NINDS_000846; Spectrum5_001175; SPBio_002078; KBioGR_001883
Trade NameCitanest
[ICD9: 338   ICD10: R52]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCCCNC(C)C(=O)NC1=CC=CC=C1C    
Therapeutic ClassAnesthetics
CAS NumberCAS 721-50-6
PubChem Compound IDCID 4906.
PubChem Substance IDSID 9734.
SuperDrug ATC IDN01BB04
SuperDrug CAS ID000721506;
TargetSodium channel protein type 5 subunit alphaBlocker[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076290 To Reference
Ref 2Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543